Sarah Butler Discusses IRA and Commercial Strategy With ConnectiveRx
On June 4, ADVI Health’s chief commercial officer, Sarah Butler, sat down with Chris Dowd of ConnectiveRx, Richard Fahrer of Pfizer, and Don Sawyer, JD, of Streamline Therapeutics for ConnectiveRx’s webinar, Bracing the Impact: The Future of Hub, Pap, and Affordability Programs Under the Inflation Reduction Act.
In this discussion, Sarah addressed why the Inflation Reduction Act (IRA) is a top focus for Biopharma manufacturer clients and how it relates to the potential longer-term consequences on drug development. With the IRA significantly impacting pharmaceutical manufacturers from a commercial strategy standpoint, Sarah shared four main areas of concern:
- Indication Sequencing
- Launch Price Planning
- Which markets to launch in first – EU vs US
- Investments in R&D
Sarah further expands on the competitive dynamics in the industry, longer term implications for drug development and innovation, where clients should be best prepared for adaptation of IRA shifts, and more.
Listen to Sarah’s insights on ConnectiveRx.
ADVI will continue monitoring developments and the next steps. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.
CEO insights
Related articles
Real analysis from people who’ve been there
Medicare Negotiation Program Deselection: Analysis of Previously Deselected Drugs and Likely Fall 2026 Targets
Authored by Allison Schneider, MHA, and Lindsay Bealor Greenleaf, JD, MBA Under the Inflation Reduction Act, drugs selected for the …
Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy
Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …
Analysis of 340B modifier usage in Medicare Part B claims
Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
What HEOR Information Does CMS Need for Drug Price Negotiations Under the IRA?
As the Inflation Reduction Act (IRA) reshapes drug pricing policy in the United States, the Centers for Medicare and Medicaid (CMS) …
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.